Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Core Laboratories (CLB) EBITDA Margin (2022 - 2025)

Core Laboratories' EBITDA Margin history spans 4 years, with the latest figure at 19.81% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 3352.0% year-over-year to 19.81%; the TTM value through Dec 2025 reached 4.54%, down 939.0%, while the annual FY2025 figure was 4.54%, 939.0% down from the prior year.
  • EBITDA Margin reached 19.81% in Q4 2025 per CLB's latest filing, down from 18.18% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 18.18% in Q3 2025 to a low of 19.81% in Q4 2025.
  • Average EBITDA Margin over 4 years is 11.54%, with a median of 14.48% recorded in 2025.
  • Peak YoY movement for EBITDA Margin: surged 466bps in 2023, then tumbled -3352bps in 2025.
  • A 4-year view of EBITDA Margin shows it stood at 15.3% in 2022, then fell by -7bps to 14.29% in 2023, then fell by -4bps to 13.71% in 2024, then crashed by -245bps to 19.81% in 2025.
  • Per Business Quant, the three most recent readings for CLB's EBITDA Margin are 19.81% (Q4 2025), 18.18% (Q3 2025), and 14.48% (Q2 2025).